[en] The diagnosis of heart failure can sometimes be challenging for the clinician because presentation circumstances and heart failure phenotypes are varied. The identification and validation of sensitive and specific biomarkers for this condition are still a subject of intensive research. Among them, natriuretic peptides (ANP, BNP, NTproBNP) are widely used and validated as markers of heart failure. Their appropriate use and correct interpretation, however, require knowledge of their indications, specificities and limitations. The European Society of Cardiology has recently issued recommendations in this regard. This article summarizes them in order to facilitate the understanding and the use of natriuretic peptides in clinical practice. It also discusses their use in the etiological diagnosis of pleural effusions caused by heart failure.
Disciplines :
Systèmes cardiovasculaire & respiratoire
Auteur, co-auteur :
NGUYEN TRUNG, Mai-Linh ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie
TRIDETTI, Julien ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de cardiologie
ANCION, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Insuffisance cardiaque - Transplantation
Task A, Members F, Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure. Eur J Heart Fail 2016; 18:891-975.
Sarhene M, Wang Y, Wei J, et al. Biomarkers in heart failure: the past, current and future. Heart Fail Rev 2019; 24:867-903.
Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018; 391:572-80.
Mueller C, McDonald K, de Boer RA, et al. Heart failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21:715-31.
Santhekadur PK, Kumar DP, Seneshaw M, et al. The multifaceted role of natriuretic peptides in metabolic syndrome. Biomed Pharmacother 2017; 92:826-35.
Maisel A, Mueller C, Adams K Jr, et al. State of the art : using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824-39.
Martin-dupan C, Golay A. Baisse paradoxale et effet métabolique du BNP chez les obèses. Rev Med Suisse 2017; 13:660-3.
Moyes A, Hobbs A. C-type natriuretic peptide : a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci 2019; 20:2281-3003.
Ponikowski P, Voors A, Anker S, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur heart J 2016; 37:2129-200.
Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care : a position statement from the study group on biomarkers in cardiology of the ESC working group on acute cardiac care. Eur heart J 2012; 33:2001-6.
Morales-Rull JL, Bielsa S, Conde-Martel A, et al. Pleural effusions in acute decompensated heart failure : prevalence and prognostic implications. Eur J Intern Med 2018; 52:49-53.
Porcel JM. Biomarkers in the diagnosis of pleural diseases : a 2018 update. Ther Adv Respir Dis 2018; 12:1-11.
Porcel JM, Martínez-Alonso M, Cao G, Biomarkers of heart failure in pleural fluid. Chest 2009; 136:671-7.
Janda S, Swiston J. Diagnostic accuracy of pleural fluid NTpro-BNP for pleural effusions of cardiac origin : a systematic review and meta-analysis. BMC Pulm Med 2010; 10:58-69.
Han ZJ, Wu XD, Cheng JJ, et al. Diagnostic accuracy of natriuretic peptides for heart failure in patients with pleural effusion : a systematic review and updated meta-analysis. PLoS One 2015; 10:e0134376.
